Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $15.99 USD
Change Today -0.32 / -1.96%
Volume 413.0K
EPZM On Other Exchanges
As of 8:10 PM 05/1/15 All times are local (Market data is delayed by at least 15 minutes).

epizyme inc (EPZM) Key Developments

Epizyme, Inc. Announces Unaudited Consolidated Earnings Results for the First Quarter Ended March 31, 2015

Epizyme, Inc. announced unaudited consolidated earnings results for the first quarter ended March 31, 2015. For the quarter, the company reported collaboration revenue of $911,000 against $13,391,000 a year ago. Operating loss was $61,377,000 against $6,912,000 a year ago. Net loss was $61,326,000 or $1.75 per basic and diluted share against $6,884,000 or $0.22 per basic and diluted share a year ago. The decline in collaboration revenue primarily reflects the substantial completion of certain components of the company’s research obligations under its collaborations.

Epizyme, Inc. to Report Q1, 2015 Results on Apr 28, 2015

Epizyme, Inc. announced that they will report Q1, 2015 results at 4:30 PM, US Eastern Standard Time on Apr 28, 2015

Epizyme, Inc., Q1 2015 Earnings Call, Apr 28, 2015

Epizyme, Inc., Q1 2015 Earnings Call, Apr 28, 2015

Epizyme to Present Updated Data from Ongoing Phase 1 Dose Escalation Trial of EZH2 Inhibitor EPZ-6438 at International Conference on Malignant Lymphoma

Epizyme, Inc. announced that updated data from the Phase 1 portion of the ongoing Phase 1/2 study of EPZ-6438 will be presented during the 13thInternational Conference on Malignant Lymphoma (ICML), to be held in Lugano, Switzerland, June 17-20, 2015. EPZ-6438 is a first-in-class EZH2 inhibitor that Epizyme is currently studying in patients with advanced B-cell non-Hodgkin lymphomas (NHL) or advanced solid tumors. EZH2 is a histone methyltransferase (HMT) that is increasingly understood to play a potentially oncogenic role in a number of cancers. These include non-Hodgkin lymphomas; INI1-deficient cancers such as malignant rhabdoid tumors, epithelioid sarcomas and synovial sarcoma; and a range of other solid tumors. Epizyme is developing EPZ-6438, a small molecule inhibitor of EZH2 created with its proprietary product platform, for the treatment of non-Hodgkin lymphoma patients and patients with INI1-deficient solid tumors. In many human cancers, misregulated EZH2 enzyme activity results in misregulation of genes that control cell proliferation without these control mechanisms, cancer cells are free to grow rapidly. EPZ-6438 is the second HMTi to enter human clinical development (following Epizyme's DOT1L inhibitor, EPZ-5676).

Eisai Co., Ltd. and Epizyme, Inc. to Change the Scope of Collaboration for Their Partnership Initiated in March 2011 to Discover, Develop and Commercialize Cancer Therapeutics Targeting EZH2, an Epigenetic Enzyme

Eisai Co., Ltd. and Epizyme, Inc. have agreed to change the scope of collaboration for their partnership initiated in March 2011 to discover, develop and commercialize cancer therapeutics targeting EZH2, an epigenetic enzyme. In March 2011, Eisai and Epizyme entered into a collaboration agreement concerning the discovery, development and commercialization of cancer therapeutics targeting the epigenetic enzyme EZH2 for the treatment of non-Hodgkin B-cell lymphoma and other cancers. Under this agreement, Eisai has been conducting a phase I/II clinical study of the EZH2 inhibitor E7438 (Epizyme development code: EPZ-6438) in patients with advanced solid tumors or non-Hodgkin B-cell lymphoma. Eisai and Epizyme have revised the scope of their partnership for worldwide development and commercialization rights for anticancer therapies targeting EZH2, including E7438, with Epizyme assuming responsibility for development and commercialization in regions outside of Japan and Eisai retaining responsibility for development and commercialization within Japan as well as having the right of first negotiation for licensing rights in Asia. The decision to change the scope of the partnership was agreed upon by the two companies in consideration of the priorities of each company's pipeline strategy and the maximization of the potential value of the compounds including E7438. Based on this change in the agreement, Eisai will receive from Epizyme a contractual one-time payment as well as milestone payments as projects progress and marketing authorization is obtained. The companies will pay royalties to one another dependent upon on the sales in each company's respective sales regions after launch. Eisai considers oncology a therapeutic area of focus and is committed to the development of new anticancer agents and treatments for supportive care. Eisai strives to further contribute to addressing the diverse needs of, and increasing the benefits provided to, patients with cancer and their families.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
EPZM:US $15.99 USD -0.32

EPZM Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for EPZM.
View Industry Companies

Industry Analysis


Industry Average

Valuation EPZM Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 19.3x
Price/Book 3.0x
Price/Cash Flow NM Not Meaningful
TEV/Sales 14.3x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact EPIZYME INC, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at